How should leucovorin (folinic acid) be dosed and modified after a 6 g methotrexate infusion for primary central nervous system lymphoma?

Leucovorin Dosing After 6g Methotrexate in PCNSL

For a 6g methotrexate infusion in PCNSL, start leucovorin at 15 mg IV/PO/IM every 6 hours beginning 24 hours after the start of methotrexate, continuing for 10 doses (60 hours total), and adjust based on methotrexate levels and renal function. 1

Standard Leucovorin Rescue Protocol

The FDA-approved leucovorin dosing for high-dose methotrexate (though based on 12-15 g/m² protocols) provides the framework that applies to 6g dosing in PCNSL 1:

Initial Dosing

• Start time: 24 hours after beginning methotrexate infusion
• Standard dose: 15 mg (approximately 10 mg/m²) every 6 hours
• Duration: 10 doses over 60 hours
• Route: IV, PO, or IM (use parenteral route if GI toxicity, nausea, or vomiting present)
• Critical: Never administer leucovorin intrathecally

Essential Monitoring Requirements

Monitor daily (at minimum):

• Serum methotrexate levels
• Serum creatinine
• Continue hydration and urinary alkalinization (pH ≥ 7.0) until methotrexate level < 0.05 micromolar 1

Dose Modification Algorithm

Normal Methotrexate Elimination

Expected levels:

• ~10 micromolar at 24 hours
• ~1 micromolar at 48 hours
• <0.2 micromolar at 72 hours

Action: Continue standard 15 mg every 6 hours for 10 doses 1

Delayed Late Elimination

Levels:

• 0.2 micromolar at 72 hours

• 0.05 micromolar at 96 hours

Action: Continue 15 mg every 6 hours until methotrexate level < 0.05 micromolar 1

Delayed Early Elimination and/or Acute Renal Injury

Levels:

• ≥50 micromolar at 24 hours, OR
• ≥5 micromolar at 48 hours, OR
• ≥100% increase in serum creatinine at 24 hours (e.g., 0.5→1.0 mg/dL or higher)

Action:

1. Escalate to 150 mg IV every 3 hours until methotrexate < 1 micromolar
2. Then reduce to 15 mg IV every 3 hours until methotrexate < 0.05 micromolar
3. Maintain aggressive hydration and urinary alkalinization
4. Monitor fluid/electrolyte status closely 1

Critical Clinical Considerations

Timing Matters for Efficacy

While the FDA label specifies 24-hour rescue initiation, do not delay beyond 36 hours from methotrexate start, as delays to 42-48 hours cause considerable toxicity 2. The 24-hour timepoint represents optimal safety.

Avoid Excessive Leucovorin Dosing

Recent evidence suggests cumulative FA doses >350 mg/m²/treatment cycle are associated with inferior progression-free survival (HR 2.2 per 100 mg/m² increase) in PCNSL patients, without reducing toxicity 3. This underscores the importance of using protocol-specified doses rather than empirically escalating rescue beyond what methotrexate levels dictate.

Levoleucovorin as Alternative

Levoleucovorin (the active L-isomer) can substitute for leucovorin during supply shortages with comparable safety, lower rescue utilization, and reduced cost, though this requires dose adjustment as it is twice as potent 4.

Common Pitfalls to Avoid

1. Never give leucovorin intrathecally - this is explicitly contraindicated and potentially fatal 1

2. Don't stop rescue prematurely - continue until methotrexate level documented < 0.05 micromolar, not just when patient feels better

3. Don't ignore drug interactions - reconsider medications that interfere with methotrexate elimination or albumin binding when toxicity or delayed clearance occurs 1

4. Don't use fixed 60-hour duration in all patients - extend rescue if significant clinical toxicity observed (total 14 doses over 84 hours in subsequent cycles) 1

5. Ensure adequate alkalinization - urine pH must be ≥7.0; check before methotrexate and adjust with sodium bicarbonate as needed 5